Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thiophene-based vitronectin receptor antagonists.

Monica Bubenik1, Karen Meerovitch, Frédéric Bergeron

  • 1Shire BioChem Inc., 275 Armand-Frappier Blvd., Laval, Québec, Canada H7V 4A7. mbubenik@ca.shire.com

Bioorganic & Medicinal Chemistry Letters
|February 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of short-acting beta-2 agonists delivered by metered-dose inhaler with spacer versus nebulizer in acute asthma exacerbations: a systematic review and meta-analysis.

The Journal of asthma : official journal of the Association for the Care of Asthma·2026
Same author

The Implementation of a Business Process Model and Notation for Modeling Patient Health Care Trajectories: Systematic Review.

Journal of medical Internet research·2026
Same author

Intersectoral interventions for people living with obesity: a scoping review and bibliometric analysis.

BMC public health·2026
Same author

Towards the development of a framework for monitoring and evaluating the multidimensional sustainability of healthcare organisations: a scoping review protocol.

BMJ open·2026
Same author

Association of Advanced Access With Primary Care Performance: A Systematic Review.

Annals of family medicine·2026
Same author

Public Healthcare Procurement Strategies in Response to the COVID-19 Pandemic: A Scoping Review.

International journal of health policy and management·2026

Researchers developed novel thiophene-based alpha(v)beta(3) antagonists. These compounds show varied selectivity for integrins and possess antiangiogenic properties, impacting blood vessel formation.

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Integrin alpha(v)beta(3) is a key target for antiangiogenic therapies.
  • Developing selective antagonists is crucial for therapeutic efficacy and minimizing side effects.
  • Thiophene scaffolds offer a promising structural basis for drug discovery.

Purpose of the Study:

  • To synthesize and evaluate novel alpha(v)beta(3) antagonists based on a thiophene scaffold.
  • To assess the in vitro biological activity and selectivity of these compounds against various integrins.
  • To investigate the antiangiogenic potential of the synthesized antagonists.

Main Methods:

  • Synthesis of thiophene-based compounds via two distinct chemical routes.
  • In vitro evaluation of antagonist activity against alpha(v)beta(3), alpha(IIb)beta(3), alpha(v)beta(5), and alpha(5)beta(1) integrins.

Related Experiment Videos

  • Assessment of antiangiogenic effects using the chick chorioallantoic membrane (CAM) assay.

    • Main Results:

    • Several structurally similar alpha(v)beta(3) antagonists were successfully synthesized.
    • Compounds exhibited differential selectivity profiles towards alpha(IIb)beta(3), alpha(v)beta(5), and alpha(5)beta(1) integrins.
    • The synthesized antagonists demonstrated significant antiangiogenic activity in the CAM assay.

    Conclusions:

    • Thiophene-based compounds represent a viable scaffold for developing selective integrin antagonists.
    • These antagonists hold potential for antiangiogenic therapies by inhibiting new blood vessel formation.
    • Further investigation into their therapeutic applications is warranted.